Compound W Maximum Strength One Step Invisible

Salicylic Acid


Medtech Products Inc.
Human Otc Drug
NDC 63029-596
Compound W Maximum Strength One Step Invisible also known as Salicylic Acid is a human otc drug labeled by 'Medtech Products Inc.'. National Drug Code (NDC) number for Compound W Maximum Strength One Step Invisible is 63029-596. This drug is available in dosage form of Plaster. The names of the active, medicinal ingredients in Compound W Maximum Strength One Step Invisible drug includes Salicylic Acid - 4 mg/1 . The currest status of Compound W Maximum Strength One Step Invisible drug is Active.

Drug Information:

Drug NDC: 63029-596
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Compound W Maximum Strength One Step Invisible
Also known as the trade name. It is the name of the product chosen by the labeler.
Proprietary Name Base: Compound W
The base of the Brand/Proprietary name excluding its suffix.
Proprietary Name Suffix: Maximum Strength One Step Invisible
A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Salicylic Acid
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Medtech Products Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Plaster
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SALICYLIC ACID - 4 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 15 Mar, 2014
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 09 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part358B
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Medtech Products Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:240559
1086356
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:O414PZ4LPZ
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63029-596-1414 PLASTER in 1 CARTON (63029-596-14)15 Mar, 2014N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose wart remover

Product Elements:

Compound w maximum strength one step invisible salicylic acid salicylic acid salicylic acid lanolin polybutene (1400 mw) natural latex rubber

Indications and Usage:

Use for the removal of common and plantar warts the common wart is easily recognized by the rough “cauliflower-like” appearance on the surface the plantar wart is recognized by its location only on the bottom of the foot, its tenderness, and the interruption of the footprint pattern

Warnings:

Warnings for external use only do not use on irritated skin or on any area that is infected or reddened on moles, birthmarks, warts with hair growing from them, genital warts or warts on the face or mucous membranes if you have diabetes or poor blood circulation stop use and ask a doctor if discomfort persists keep out of reach of children. if swallowed, get medical help or contact a poison control center (1-800-222-1222) right away.

Do Not Use:

Warnings for external use only do not use on irritated skin or on any area that is infected or reddened on moles, birthmarks, warts with hair growing from them, genital warts or warts on the face or mucous membranes if you have diabetes or poor blood circulation stop use and ask a doctor if discomfort persists keep out of reach of children. if swallowed, get medical help or contact a poison control center (1-800-222-1222) right away.

Dosage and Administration:

Directions wash affected area may soak wart in warm water for 5 minutes dry area thoroughly remove medicated pad from backing paper by pulling from center of pad apply repeat procedure every 48 hours as needed (until wart is removed) for up to 12 weeks

Stop Use:

Stop use and ask a doctor if discomfort persists

Package Label Principal Display Panel:

Principal display panel compound w salicylic acid wart remover 14 medicated strips principal display panel compound w wart remover 14 medicated strips

Further Questions:

Questions? 1-800-443-4908 compoundw.com ©2016 distributed by medtech products inc. tarrytown, ny 10591 a prestige brands company made in japan


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.